NIH R01 · 2024
The role of Kit signaling in taste bud regeneration
Cancer patients receiving most types of chemotherapy experience dysgeusia, i.e., distorted taste, which is associated with depression, malnutrition, morbid weight loss, and interruption of life-prolonging treatment. Cells within taste buds are continually and rapidly renewed, and this constant turnover makes taste prone to disruption by cancer therapies. However, the underlying and likely multiple mechanisms perturbed by cancer drugs that cause dysgeusia are not known. Here we focus on a small subset of six tyrosine kinase inhibitors (TKIs) used routinely to manage metastatic renal cell carcinoma (mRCC). These drugs target tumors by inhibiting VEGFR1-3 and PDGFR receptor tyrosine kinases…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.